AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Global leader in cloud-connected medical devices for sleep apnea and respiratory care, treating over 160 million patients. Software-driven digital health platform.

Aging Population Stocks

ResMed is a global leader in cloud-connected devices for sleep apnea and respiratory care, treating over 160 million patients and benefiting from aging population-driven demand for respiratory therapy.

Key Financials RMD

Price $252.55
Change (1D) +2.78%
Change (30D) +4.85%
Change (60D) +3.20%
Change (90D) -10.25%
Change (180D) +3.18%
Change (1Y) +6.74%
Change (5Y) +26.36%
P/E Ratio 32.09
EPS (TTM) $7.87
52-Week Range $199.92 — $293.81
50-Day MA $252.89
Volume 971.0K

Data updated Feb 15 · Source: Twelve Data

4.3
1 reviews
Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Claude Opus 4.6
AI Review
4.3/5

ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.

Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Feb 15, 2026
ResMed Screenshot

Added: Feb 15, 2026

resmed.com

Latest from Otrai

How to Backtest a Trading Strategy: Methods, Pitfalls, and What the Results Actually Mean

How to Backtest a Trading Strategy: Methods, Pitfalls, and What the Results Actually Mean

Every trader has a strategy that looks great in their head. Backtesting is how you find out whether it actually works. Here is how to test strategies properly, what metrics matter, and why most backtest results are too good to be true.

Risk-Reward Ratios: How to Set Targets That Make Your Strategy Profitable

Risk-Reward Ratios: How to Set Targets That Make Your Strategy Profitable

A risk-reward ratio compares how much you stand to lose on a trade to how much you stand to gain. It is arguably the most important number in your trading plan, because it determines whether your strategy can survive a normal losing streak.

Trading the News: How Economic Events Move Forex and What to Do About It

Trading the News: How Economic Events Move Forex and What to Do About It

Every month, a handful of economic data releases move the forex market more in five minutes than most sessions move in five days. Non-Farm Payrolls, CPI prints, and central bank rate decisions create violent spikes, whipsaws, and trend shifts that can make or break a trading account.

What Is a CFD? How Contracts for Difference Work and When to Use Them

What Is a CFD? How Contracts for Difference Work and When to Use Them

A CFD is a contract between you and your broker to exchange the difference in an asset's price from when you open the trade to when you close it. You never own the underlying asset. That single distinction shapes everything about how CFDs work, what they cost, and why regulators treat them differently from traditional investing.